Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Total Liabilities (2016 - 2025)

Acro Biomedical has reported Total Liabilities over the past 10 years, most recently at $401062.0 for Q4 2025.

  • Quarterly results put Total Liabilities at $401062.0 for Q4 2025, up 22.67% from a year ago — trailing twelve months through Dec 2025 was $401062.0 (up 22.67% YoY), and the annual figure for FY2025 was $401062.0, up 22.67%.
  • Total Liabilities for Q4 2025 was $401062.0 at Acro Biomedical, down from $436942.0 in the prior quarter.
  • Over the last five years, Total Liabilities for ACBM hit a ceiling of $436942.0 in Q3 2025 and a floor of $60158.0 in Q2 2021.
  • Median Total Liabilities over the past 5 years was $284318.5 (2021), compared with a mean of $246499.2.
  • Biggest five-year swings in Total Liabilities: tumbled 74.71% in 2021 and later skyrocketed 188.18% in 2023.
  • Acro Biomedical's Total Liabilities stood at $117370.0 in 2021, then surged by 71.35% to $201116.0 in 2022, then skyrocketed by 56.86% to $315473.0 in 2023, then rose by 3.64% to $326946.0 in 2024, then grew by 22.67% to $401062.0 in 2025.
  • The last three reported values for Total Liabilities were $401062.0 (Q4 2025), $436942.0 (Q3 2025), and $370797.0 (Q2 2025) per Business Quant data.